Comments
Aurobindo Pharma Ltd’s shares were up by 0.50 per cent following the company’s announcement of receiving final approval from the US Food & Drug Administration (USFDA) for Darunavir tablets, 600 mg and 800 mg. The approved product, which is bioequivalent to Janssen’s Prezista tablets, is set to launch on November 29, 2023, with an estimated market size of $274.8 million.
Aurobindo achieved a total of 500 ANDA approvals from the USFDA, including 478 Final approvals and 22 tentative approvals. Darunavir tablets are indicated for the treatment of HIV-1 infection in patients aged three years and older.
The shares were up by 0.50 per cent to ₹1,022.65 at 12 pm on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.